melanotan 1 results: Frequently asked questions

Verify your UV exposure. Melanotan-1 requires ultraviolet light to trigger melanogenesis. If you've been dosing daily but avoiding sun exposure entirely, melanin production remains minimal regardless of peptide saturation. Introduce 10–15 minutes of midday sun or 0.5 MED UVB exposure every other day and reassess after 4–5 additional days. If tanning still doesn't appear and you're Fitzpatrick Type I, extend the loading phase to 21 days. Some phenotypes require longer melanocyte priming before visible pigmentation occurs.

This reflects differential melanocyte density and UV exposure patterns across anatomical regions. Arms and face receive more cumulative UV than covered areas like the torso or inner thighs. The fix: during week two, expose undertanned areas to targeted UV (e.g., torso-focused sunbathing for 10 minutes while arms are covered). Melanin distribution evens out by day 14–16 once all regions receive comparable UV dosing.

Melanin turnover accelerates without sustained MC1R stimulation. If you're dosing 0.25mg twice weekly but fading within 14 days, either increase maintenance frequency to 0.25mg three times weekly or incorporate brief UV exposure (10 minutes) once weekly. Exfoliation also strips melanin-rich keratinocytes from the stratum corneum. Avoid aggressive physical exfoliants and retinoid use during maintenance if you want sustained colour.

Nausea, facial flushing, and transient appetite suppression occur in 30–50% of users during the first 7–10 days due to MC4R cross-activation in the hypothalamus and peripheral vasodilation. These effects typically resolve as receptor desensitization occurs. Mitigation strategies: inject before bedtime to sleep through peak side effects (1–3 hours post-administration), reduce loading dose to 0.25mg daily and extend the timeline by 5–7 days, or split the daily dose into two 0.5mg injections 12 hours apart. Severe nausea that persists beyond day 10 or prevents consistent dosing justifies protocol revision. The Melanotan-1 results timeline extends when side effects force missed doses.

This is expected during the first 3–4 weeks when melanin density has not yet reached saturation. Melanin-laden keratinocytes naturally shed every 28–45 days, so early-stage pigmentation disappears within 7–10 days if dosing stops before peak accumulation. Once you reach week 6–8 and peak pigmentation is established, transitioning to maintenance dosing (0.25–0.5mg twice weekly) sustains the tan for months. The key is completing the full loading phase before reducing frequency. Premature transition to maintenance dosing resets the Melanotan-1 results timeline entirely.

First, verify reconstitution and storage integrity. Denatured peptides produce zero MC1R activation regardless of dose. If the peptide was stored correctly, assess UV exposure: have you received controlled sun or UVB exposure at least three times weekly? Melanin synthesis without UV stimulation is minimal. Finally, consider baseline skin type. Fitzpatrick type I may require 14–18 days before visible pigmentation appears, not 10–12 days. Extend the loading phase to 21 days before concluding non-response; true MC1R insensitivity is rare but documented in individuals with specific receptor polymorphisms that reduce afamelanotide binding affinity.

This is the most common one-week outcome and indicates the peptide is working correctly. Mole darkening reflects localized melanocyte hyperactivity. These cells have higher MC1R density than surrounding skin and respond faster to α-MSH analogs. Baseline skin tone changes lag by 7–14 days because diffuse melanin deposition requires sustained tyrosinase activity across all epidermal melanocytes, not just pigmented lesions. Continue your current dose and add UV exposure if you haven't already. Pigment will follow.

Verify dosing adherence first. Missing more than two consecutive injections during loading phase resets melanogenic signalling and delays visible response by 1–2 weeks. If dosing was consistent, MC1R receptor polymorphisms are the likely constraint. Individuals with non-functional MC1R variants (common in red-haired, Type I skin populations) require 8–10 weeks to reach pigmentation levels that Type II–III individuals achieve in 4–6 weeks. Consider extending the loading phase to 8 weeks at 1mg every 48 hours before concluding non-response. Clinical data shows that fewer than 5% of subjects with functional MC1R fail to respond to properly dosed afamelanotide.

Reduce the dose by 50% and split it into two daily injections (e.g., 0.25mg morning and evening instead of 0.5mg once daily). Nausea from melanotan-1 peaks 30–90 minutes post-injection and correlates with rapid MC1R activation in the hypothalamus, which modulates appetite and nausea signaling. Splitting the dose flattens the plasma concentration curve and reduces peak receptor occupancy without compromising cumulative melanogenic effect. If nausea persists beyond 72 hours at reduced dose, discontinue and consider restarting at 0.1mg daily. Some subjects require ultra-gradual titration.

Melanin density will plateau at the level achieved by day 30, then gradually fade over 8–12 weeks as keratinocytes shed through normal epidermal turnover and no new melanosomes are produced to replace them. Stopping after one month means you've built approximately 60% of the pigmentation the peptide can deliver. Maintenance dosing (1mg weekly) would sustain that level indefinitely, while stopping returns you to baseline within three months. Clinical trials demonstrated that subjects who discontinued afamelanotide after loading phase lost 70–80% of gained pigmentation within 16 weeks. If the goal was temporary darkening for a specific event, stopping at day 30 is viable. If the goal was sustained photoprotection, transition to maintenance.

This is the expected physiological response. Areas with pre-existing melanocyte activity and higher MC1R density respond first because the baseline melanogenic machinery is already active. Melanotan-1 amplifies it. Freckles, moles, and areolae darken within 10–14 days, while previously unpigmented skin takes 18–24 days to show equivalent darkening as new melanosomes are synthesised and transferred. The pigmentation pattern evens out by weeks 5–6 as keratinocytes in all regions accumulate eumelanin. Disproportionate darkening at day 30 does not indicate overdosing or adverse response. It confirms the peptide is functioning as intended.

This is expected. Melanotan-1 doesn't produce uniform pigmentation without UV. The peptide upregulates melanin synthesis capacity across all melanocytes, but photoactivation occurs only where UV light reaches the skin. If your face and arms are darkening but your torso isn't, it reflects differential UV exposure, not peptide inefficacy. To achieve more uniform tone, expose non-tanned areas during UV sessions or continue the protocol long enough that baseline melanin elevation (the slight systemic increase in eumelanin even without UV) becomes noticeable. This typically requires 6–8 weeks.

Reduce your dose temporarily. Nausea from Melanotan-1 is dose-dependent and MC4R-mediated, meaning it scales with plasma concentration. If nausea persists past day 7–10 on a 1mg daily dose, drop to 0.5mg for 5–7 days to allow receptor desensitisation, then re-escalate gradually. Persistent nausea beyond two weeks at any dose is uncommon and may indicate contaminated peptide, improper reconstitution (using saline instead of bacteriostatic water can alter osmolarity and cause GI distress), or an unrelated GI condition coinciding with peptide use. If symptoms don't resolve with dose reduction, discontinue and consult a prescribing physician.

Continue the protocol. You're likely still within the normal biological timeline. Melanin synthesis latency means most users don't see meaningful pigment accumulation until weeks three or four, particularly if baseline skin tone is fair (Type I–II) or UV exposure has been inconsistent. Verify that you're injecting subcutaneously (not intramuscularly, which delays absorption), that reconstituted peptide has been stored at 2–8°C continuously, and that UV sessions are occurring at least three times per week at 0.5–0.7 MED per session. If all variables are controlled and you still see zero change by week five, MC1R density variation may be limiting response. Some individuals with very low MC1R expression require higher doses or longer protocols to achieve visible results.

Continue the protocol. Absence of visible tanning at one week is normal and expected. The peptide's effect on melanin synthesis is cumulative, not immediate. Verify that your reconstituted peptide was stored at 2–8°C and that injections are subcutaneous (not intramuscular, which reduces bioavailability). If existing moles or freckles haven't darkened even slightly by day 10, consider increasing the dose from 0.25mg to 0.5mg or adding controlled UV exposure three times weekly to stimulate melanin transfer.